This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

George W. Paulson, MD

Arch Neurol. 1994;51(8):754-756.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THERE ARE few conditions that have more significance for rational practice and neurologic science than does Parkinson's disease (PD), and PD remains in the forefront in discussions of abiotrophy and degeneration, dementia and cognition, animal models and receptors, and genetic and environmental causation, as well as in the discussion of protective, symptomatic, and surgical therapy. One apparent advance since levodopa revolutionized therapy is special interest in movement disorders by many neurologists. Most general neurologists are now skilled at, or at least fascinated by, disorders of movement. Neurologists may feel not just adequately informed but actually bombarded by clinical reports, pharmaceutically sponsored symposia, and definitive experts. Nevertheless, puzzles in the diagnosis of PD, uncertainty in choice of therapy, unsatisfactory results of long-term management, and end-stage despair remain common experiences for us all. What drug to start, what to avoid, what to combine, and how to follow up the patient are not . . . [Full Text PDF of this Article]

Author Affiliations
1654 Upham Dr, MH 443 Columbus, OH 43210

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?